{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:34:00Z","timestamp":1763415240063},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T00:00:00Z","timestamp":1253577600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s10067-009-1233-9","type":"journal-article","created":{"date-parts":[[2009,9,21]],"date-time":"2009-09-21T05:35:17Z","timestamp":1253511317000},"page":"1365-1373","source":"Crossref","is-referenced-by-count":20,"title":["A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis"],"prefix":"10.1007","volume":"28","author":[{"given":"Astrid","family":"Wiens","sequence":"first","affiliation":[]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[]},{"given":"Rafael","family":"Venson","sequence":"additional","affiliation":[]},{"given":"M\u00f4nica Cavichiolo","family":"Grochocki","sequence":"additional","affiliation":[]},{"given":"Michel Fleith","family":"Otuki","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,9,22]]},"reference":[{"issue":"Suppl 1","key":"1233_CR1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.rheumatology.a031494","volume":"39","author":"P Tugwell","year":"2000","unstructured":"Tugwell P (2000) Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford) 39(Suppl 1):43\u201347","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1233_CR2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ncprheum0797","volume":"4","author":"ML Moss","year":"2008","unstructured":"Moss ML, Sklair-Tavron L, Nudelman R (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4(6):300\u2013309","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"9410","key":"1233_CR3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675\u2013681","journal-title":"Lancet"},{"issue":"3","key":"1233_CR4","first-page":"151","volume":"47","author":"M B\u00e9rtolo","year":"2007","unstructured":"B\u00e9rtolo M, Brenol C, Schainberg C, Neubarth F (2007) Atualiza\u00e7\u00e3o do consenso brasileiro no diagn\u00f3stico e tratamento da artrite reumat\u00f3ide. Rev Bras Reumatol 47(3):151\u2013159","journal-title":"Rev Bras Reumatol"},{"issue":"12","key":"1233_CR5","first-page":"2334","volume":"34","author":"A Fernandez-Nebro","year":"2007","unstructured":"Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG et al (2007) Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 34(12):2334\u20132342","journal-title":"J Rheumatol"},{"issue":"4","key":"1233_CR6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10067-007-0790-z","volume":"27","author":"K Kanbe","year":"2008","unstructured":"Kanbe K, Inoue K, Inoue Y, Suzuki Y (2008) Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. Clin Rheumatol 27(4):497\u2013501","journal-title":"Clin Rheumatol"},{"issue":"9194","key":"1233_CR7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932\u20131939","journal-title":"Lancet"},{"issue":"4","key":"1233_CR8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","volume":"52","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D et al (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52(4):1020\u20131030","journal-title":"Arthritis Rheum"},{"key":"1233_CR9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ard.2003.013961","volume":"63","author":"FC Breedveld","year":"2004","unstructured":"Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR et al (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63:149\u2013155","journal-title":"Ann Rheum Dis"},{"issue":"9285","key":"1233_CR10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903\u2013911","journal-title":"Lancet"},{"issue":"8","key":"1233_CR11","first-page":"554","volume":"60","author":"RG Silva","year":"2003","unstructured":"Silva RG, Vannucci AB, Latorre LC, Zerbini CAF (2003) Artrite reumat\u00f3ide. Rev Bras Med 60(8):554\u2013577","journal-title":"Rev Bras Med"},{"issue":"11","key":"1233_CR12","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.clinthera.2008.11.007","volume":"30","author":"E Zintzaras","year":"2008","unstructured":"Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM (2008) Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 30(11):1939\u20131955","journal-title":"Clin Ther"},{"issue":"11","key":"1233_CR13","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"EW St Clair","year":"2004","unstructured":"St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432\u20133443","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1233_CR14","first-page":"37","volume":"33","author":"T Abe","year":"2006","unstructured":"Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y et al (2006) A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33(1):37\u201344","journal-title":"J Rheumatol"},{"issue":"22","key":"1233_CR15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594\u20131602","journal-title":"N Engl J Med"},{"issue":"8","key":"1233_CR16","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","volume":"67","author":"M Schiff","year":"2008","unstructured":"Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096\u20131103","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1233_CR17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","volume":"54","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P et al (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54(4):1075\u20131086","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1233_CR18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1479-8077.2006.00186.x","volume":"9","author":"F-C Zhang","year":"2006","unstructured":"Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q et al (2006) Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 9(2):127\u2013130","journal-title":"APLAR J Rheumatol"},{"issue":"4","key":"1233_CR19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/art.20123","volume":"50","author":"PC Taylor","year":"2004","unstructured":"Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA et al (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50(4):1107\u20131116","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1233_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"6","key":"1233_CR21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727\u2013735","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1233_CR22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.2004.034769","volume":"65","author":"A Hakkinen","year":"2006","unstructured":"Hakkinen A, Kautiainen H, Hannonen P, Ylinen J, Makinen H, Sokka T (2006) Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis 65(1):30\u201334","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1233_CR23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193\u2013206","journal-title":"Psychol Methods"},{"issue":"1","key":"1233_CR24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"MA Quinn","year":"2005","unstructured":"Quinn MA, Conaghan PG, O'connor PJ, Karim Z, Greenstein A, Brown A et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1):27\u201335","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1233_CR25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","volume":"54","author":"JS Smolen","year":"2006","unstructured":"Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702\u2013710","journal-title":"Arthritis Rheum"},{"key":"1233_CR26","unstructured":"Food and Drug Administration (2006) Arthritis Drugs Advisory Committee: Safety update on TNF antagonists: infliximab and etanercept. http:\/\/wwwfdagov\/medwatch\/SAFETY\/2006\/May_PIs\/Remicade_PIpdfhttp:\/\/wwwfdagov\/medwatch\/SAFETY\/2006\/May_PIs\/Remicade_PIpdf"},{"issue":"8","key":"1233_CR27","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368\u20132376","journal-title":"Arthritis Rheum"},{"issue":"15","key":"1233_CR28","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098\u20131104","journal-title":"N Engl J Med"},{"issue":"4","key":"1233_CR29","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar2001","volume":"8","author":"B Cruyssen van der","year":"2006","unstructured":"van der Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F et al (2006) Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8(4):R112","journal-title":"Arthritis Res Ther"},{"key":"1233_CR30","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/ard.2008.090860","volume":"68","author":"K Pavelka","year":"2009","unstructured":"Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L et al (2009) Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 68:1285\u20131289","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1233-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-009-1233-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1233-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T08:51:36Z","timestamp":1559119896000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-009-1233-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,22]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s10067-009-1233-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,22]]}}}